Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 - Malta

SAFETY DATA SHEET



AQUATOP VIRTA 22 - RAL 7015

SECTION 1: Identification of the substance/mixture and of the company/ undertaking

1.1	Product identifier	
P	roduct name	

: AQUATOP VIRTA 22 - RAL 7015

1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use: Paint.

1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

responsible for this SDS

National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

1.4 Emergency telephone number

National advisory body/Poison Centre

 Telephone number
 : Malta Competition and Consumer Affairs Authority (MCCAA): +356 2395 2000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Product definition : Mixture <u>Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]</u> Not classified.

The product is not classified as hazardous according to Regulation (EC) 1272/2008 as amended. See Section 11 for more detailed information on health effects and symptoms.

2.2 Label elements		
Signal word	1	No signal word.
Hazard statements	1	No known significant effects or critical hazards.
Precautionary statements		
Prevention	1	Not applicable.
Response	1	Not applicable.
Storage	1	Not applicable.
Disposal	1	Not applicable.
Supplemental label elements	:	Contains adipohydrazide, 1,2-benzisothiazol-3(2H)-one and 2-methyl-2H-isothiazol- 3-one. May produce an allergic reaction. Safety data sheet available on request. Warning! Hazardous respirable droplets may be formed when sprayed. Do not breathe spray or mist.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	:	

2.3 Other hazards

Date of issue/Date of revision: 30/05/2025Date of previous issue: 06/11/2023AQUATOP VIRTA 22 - RAL 7015

SECTION 2: Hazards identification

Product meets the criteria : This mixture does not contain any substances that are assessed to be a PBT or a for PBT or vPvB according vPvB. to Regulation (EC) No. 1907/2006, Annex XIII

Other hazards which do : None known. not result in classification

SECTION 3: Composition/information on ingredients

3.2 Mixtures	: Mixture				
Product/ingredient name	Identifiers	%	Classification	Specific Conc. Limits, M-factors and ATEs	Туре
2-(2-butoxyethoxy)ethanol	REACH #: 01-2119475104-44 EC: 203-961-6 CAS: 112-34-5 Index: 603-096-00-8	≤3	Eye Irrit. 2, H319	-	[1] [2]
titanium dioxide	REACH #: 01-2119489379-17 EC: 236-675-5 CAS: 13463-67-7	≤3	Carc. 2, H351 (inhalation)	-	[1] [*]
adipohydrazide	REACH #: 01-2119962900-36 EC: 213-999-5 CAS: 1071-93-8	<1	Skin Sens. 1, H317 Aquatic Chronic 2, H411	-	[1]
1,2-benzisothiazol-3(2H)- one	EC: 220-120-9 CAS: 2634-33-5 Index: 613-088-00-6	<0.036	Acute Tox. 4, H302 Acute Tox. 2, H330 Skin Irrit. 2, H315 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410	ATE [Oral] = 450 mg/kg ATE [Inhalation (dusts and mists)] = 0.21 mg/l Skin Sens. 1, H317: C $\geq 0.036\%$ M [Acute] = 1 M [Chronic] = 1	[1]
2-methyl-2H-isothiazol- 3-one	EC: 220-239-6 CAS: 2682-20-4 Index: 613-326-00-9	<0.0015	Acute Tox. 3, H301 Acute Tox. 3, H311 Acute Tox. 2, H330 Skin Corr. 1B, H314 Eye Dam. 1, H318 Skin Sens. 1A, H317 Aquatic Acute 1, H400 Aquatic Chronic 1, H410 EUH071	ATE [Oral] = 100 mg/kg ATE [Dermal] = 300 mg/kg ATE [Inhalation (dusts and mists)] = 0.11 mg/l Skin Sens. 1, H317: C $\geq 0.0015\%$ M [Acute] = 10 M [Chronic] = 1	[1]
			See Section 16 for the full text of the H statements declared above.		

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section. Type

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[*] The classification as a carcinogen by inhalation applies only to mixtures placed on the market in powder form containing 1% or more of titanium dioxide particles with aerodynamic diameter \leq 10 µm not bound within a matrix.

Occupational exposure limits, if available, are listed in Section 8.

Date of issue/Date of revision AQUATOP VIRTA 22 - RAL 7015 :06/11/2023

SECTION 4: First aid measures

4.1 Description of first aid measures			
Eye contact	: Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.		
Inhalation	: Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.		
Skin contact	 Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur. 		
Ingestion	: Wash out mouth with water. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.		
Protection of first-aiders	: No action shall be taken involving any personal risk or without suitable training.		

4.2 Most important symptoms and effects, both acute and delayed
Over-exposure signs/symptoms

Eye contact	: No specific data.
Inhalation	: No specific data.
Skin contact	: No specific data.
Ingestion	: No specific data.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	 Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments	: No specific treatment.

SECTION 5: Firefighting measures

5.1 Extinguishing media		
Suitable extinguishing media	:	Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	:	None known.
5.2 Special hazards arising f	ron	the substance or mixture
Hazards from the substance or mixture	:	In a fire or if heated, a pressure increase will occur and the container may burst.
Hazardous combustion products	:	Decomposition products may include the following materials: carbon dioxide carbon monoxide metal oxide/oxides
5.3 Advice for firefighters		
Special protective actions for fire-fighters	-	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters	:	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents.

: 30/05/2025 Date of previous issue

SECTION 6: Accidental release measures

6.1 Personal precautions, pro	6.1 Personal precautions, protective equipment and emergency procedures			
For non-emergency personnel	: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilt material. Put on appropriate personal protective equipment.			
For emergency responders	: If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".			
6.2 Environmental precautions	: Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).			
6.3 Methods and material for	containment and cleaning up			
Small spill	: Stop leak if without risk. Move containers from spill area. Absorb with an inert material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.			
Large spill	: Stop leak if without risk. Move containers from spill area. Prevent entry into sewers water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Dispose of via a licensed waste disposal contractor. Contain and collect spillage with non-combustible, absorbent material e. g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations.			
6.4 Reference to other sections	: See Section 1 for emergency contact information. See Section 8 for information on appropriate personal protective equipment. See Section 13 for additional waste treatment information.			

SECTION 7: Handling and storage

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

7.1 Precautions for safe handling

Protective measures	: Put on appropriate personal protective equipment (see Section 8).
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

7.3 Specific end use(s)

Recommendations	: Not available.
Industrial sector specific solutions	: Not available.

SECTION 8: Exposure controls/personal protection

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

8.1 Control parameters

Occupational exposure limits

Product/ingredient name	Exposure limit values
2-(2-butoxyethoxy)ethanol	EU OEL (Europe, 1/2022)
	TWA 8 hours: 67.5 mg/m ³ .
	TWA 8 hours: 10 ppm.
	STEL 15 minutes: 101.2 mg/m ³ .
	STEL 15 minutes: 15 ppm.

Biological exposure indices

Product/ingredient name		Exposure indices				
No exposure indices known.						
Recommended monitoring : procedures	European Stand assessment of e values and mea atmospheres - C of exposure to c (Workplace atm for the measure	Id be made to monitoring standards, such as the following: lard EN 689 (Workplace atmospheres - Guidance for the exposure by inhalation to chemical agents for comparison with limit surement strategy) European Standard EN 14042 (Workplace Guide for the application and use of procedures for the assessment hemical and biological agents) European Standard EN 482 ospheres - General requirements for the performance of procedures ment of chemical agents) Reference to national guidance methods for the determination of hazardous substances will also be				
DNELs/DMELs						
Product/ingredient name		Result				
2-(2-butoxyethoxy)ethanol		DNEL - General population - Long term - Oral 6.25 mg/kg bw/day <u>Effects</u> : Systemic				
		DNEL - Workers - Long term - Inhalation 67.5 mg/m³ <u>Effects</u> : Local				
		DNEL - Workers - Short term - Inhalation 101.2 mg/m³ <u>Effects</u> : Local				
titanium dioxide		DNEL - General population - Long term - Inhalation 28 μg/m³ <u>Effects</u> : Local				
		DNEL - Workers - Long term - Inhalation 170 μg/m³ <u>Effects</u> : Local				
adipohydrazide		DNEL - Workers - Long term - Inhalation 17.5 mg/m³ <u>Effects</u> : Systemic				
1,2-benzisothiazol-3(2H)-one		DNEL - General population - Long term - Dermal 0.345 mg/kg bw/day <u>Effects</u> : Systemic				
		DNEL - Workers - Long term - Dermal 0.966 mg/kg bw/day <u>Effects</u> : Systemic				
		DNEL - General population - Long term - Inhalation 1.2 mg/m ³				

Effects: Systemic

DNEL - Workers - Long term - Inhalation 6.81 mg/m³ <u>Effects</u>: Systemic

2-methyl-2H-isothiazol-3-one

DNEL - General population - Long term - Inhalation 0.021 mg/m³ <u>Effects</u>: Local

DNEL - Workers - Long term - Inhalation 0.021 mg/m³ <u>Effects</u>: Local

DNEL - General population - Long term - Oral 0.027 mg/kg bw/day <u>Effects</u>: Systemic

DNEL - General population - Short term - Inhalation 0.043 mg/m³ Effects: Local

DNEL - Workers - Short term - Inhalation 0.043 mg/m³ Effects: Local

DNEL - General population - Short term - Oral 0.053 mg/kg bw/day <u>Effects</u>: Systemic

PNECs

Not available.

8.2 Exposure controls			
Appropriate engineering controls	: Good general ventilation should be sufficient to control worker exposure to airborn contaminants.	e	
Individual protection meas	es		
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period Appropriate techniques should be used to remove potentially contaminated clothin Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.		
Eye/face protection	Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.		
Skin protection			
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard shou be worn at all times when handling chemical products if a risk assessment indicate this is necessary.		
	Recommendations : Wear suitable gloves tested to EN374.		
	> 8 hours (breakthrough time): Nitrile gloves. thickness > 0.3 mm		
	Not recommended polyvinyl alcohol (PVA) gloves		
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.		

SECTION 8: Exposure controls/personal protection

-	
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
	Filter type (spray application): A P
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

SECTION 9: Physical and chemical properties

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

9.1 Information on basic physical and chemical properties

Appearance	
Physical state	: Liquid.
Colour	: Grey.
Odour	: Slight
Odour threshold	: Not available.
Melting point/freezing point	: Not available.
Initial boiling point and boiling range	:

	Ingredient name	°C	°F	Method
	water	100	212	
	2-(2-butoxyethoxy)ethanol	225 to 227.6	437 to 441.7	
F	lammability : Not ava	ilable.		

Fiammability
Lower and upper explosion limit
Flash point

- : Lower: Not applicable.
- Upper: Not applicable.

ŝ,

: Closed cup: >100°C (>212°F)

Auto-ignition temperature

Ingredient name	°C	°F	Method
24(2-butoxyethoxy)ethanol	210	410	DIN 51794

Decomposition temperature	1	Not available.
рН	1	₿ to 8.5 [Conc. (% w/w): 100%]
Viscosity	:	Not available.
Solubility(ies)	:	
Not available.		
Solubility in water	:	Not available.
Destition coefficients n extended		Netenpliechle

Partition coeffici	ent: n-octanol/	ι,	Not applicable.
water			

Vapour pressure

	Va	Vapour Pressure at 20°C			Vapour pressure at 50°C		
Ingredient name	mm Hg	kPa	Method	mm Hg	kPa	Method	
water	17.5	2.3					
2-(2-butoxyethoxy)ethanol	0.022	0.0029					
Relative density	: Not	available.	•				
Density	: 1.1	g/cm³					

: 1.1 g/cm³

: 30/05/2025

ŝ

:06/11/2023

7/16

Vapour density	: Not available.
Particle characteristics	
Median particle size	: Not applicable.
9.2 Other information	
9.2.1 Information with reg	ard to physical hazard classes
Explosive properties	: Not available.
Oxidising properties	: Not available.
9.2.2 Other safety charact	teristics
Not applicable.	
SECTION 10: Stabi	lity and reactivity
10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: The product is stable.
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: No specific data.

10.6 Hazardous	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.
decomposition products	should hot be produced.

: No specific data.

SECTION 11: Toxicological information

11.1 Information on hazard classes as de	fined in Regulation (EC) No 1272/2008
Acute toxicity	
Product/ingredient name	Result
2-(2-butoxyethoxy)ethanol	Rabbit - Dermal - LD50
	2700 mg/kg
	Rat - Oral - LD50
	4500 mg/kg
	<u>Toxic effects</u> : Behavioral - Tetany Lung, Thorax, or Respiration - Dyspnea Liver - Other changes
1,2-benzisothiazol-3(2H)-one	Rat - Oral - LD50
	1020 mg/kg
2-methyl-2H-isothiazol-3-one	Rat - Inhalation - LC50 Dusts and mists
	0.11 mg/l [4 hours]

Conclusion/Summary [Product] : Not available.

Acute toxicity estimates

10.5 Incompatible materials

Product/ingredient name	Oral (mg/ kg)	Dermal (mg/kg)	Inhalation (gases) (ppm)	Inhalation (vapours) (mg/l)	Inhalation (dusts and mists) (mg/l)
QUATOP VIRTA 22	N/A	N/A	N/A	699.0	N/A
2-(2-butoxyethoxy)ethanol	4500	2700	N/A	N/A	N/A
1,2-benzisothiazol-3(2H)-one	450	N/A	N/A	N/A	0.21
2-methyl-2H-isothiazol-3-one	100	300	N/A	N/A	0.11

: 30/05/2025 Date of previous issue

:06/11/2023

Version : 2 8/16 Label No : 1/14118

Product/ingredient name Result Itanium dioxide Human - Skin - Mild irritant Duration of treatment/exposure: 72 hours Amount/concentration applied: 300 ug I 1,2-benzisothiazol-3(2H)-one Human - Skin - Mild irritant Duration of treatment/exposure: 48 hours Amount/concentration applied: 5 % Conclusion/Summary [Product] : Not available.			
Finitum dioxide Human - Skin - Mild irritant Duration of treatment/exposure: 72 hours Amount/concentration applied: 300 ug 1 1,2-benzisothiazol-3(2H)-one Human - Skin - Mild irritant Duration of treatment/exposure: 48 hours Amount/concentration applied: 5 % Conclusion/Summary (Product) : Not available. Berious eve damage/eve irritation Product/ingredient name Result Rabbit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Conclusion/Summary (Product) : Not available. Respiratory corrosion/irritation Not available. Not available. Skin Conclusion/Summary (Product) : Not available. Respiratory or skin sensitization Not available. : Not available. Skin Conclusion/Summary (Product) : Not available. Conclusion/Summary (Product) : Not available. Berginatory Conclusion/Summary (Product) : Not available. Conclusion/Summary (Skin corrosion/irritation		Posult
Duration of treatment(exposure: 72 hours Amount/concentration applied: 300 ug 1 1,2-benzisothiazol-3(2H)-one Human - Skin - Mild irritant Duration of treatment(exposure: 48 hours Amount/concentration applied: 5 % Conclusion/Summary [Product] : Not available. Result Berious eve damage/eve irritation Product/ingredient name Result Product/ingredient name Result Rabbit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Skin Conclusion/Summary [Product] : Not available. Sepiratory Conclusio			
Amount/concentration applied: 300 ug l 1,2-benzisothiazol-3(2H)-one Human - Skin - Mild irritant Duration of treatment/exposure: 48 hours Amount/concentration applied: 5 % Conclusion/Summary [Product] : Not available. Serious eye damage/eye irritation Product/ingredient name F(2-butoxyethoxy)ethanol Result Rabbit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Rabbit - Eyes - Sovere irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory or skin sonsitization Not available. Skin Conclusion/Summary [Product] : Not available. Conclu	manium dioxide		
1,2-benzisothiazol-3(2H)-one Human - Skin - Mild irritant Duration of treatment/exposure; 48 hours Amount/concentration applied; 5 % Conclusion/Summary [Product] : Not available. Serious eye damage/eye irritation Product/ingredient name Result Rabbit - Eyes - Moderate irritant Duration of treatment/exposure; 24 hours Amount/concentration applied; 20 mg Rabbit - Eyes - Moderate irritant Duration of treatment/exposure; 24 hours Amount/concentration applied; 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. : Skin Conclusion/Summary [Product] : Not available. Sepiratory Conclusion/Summary [Product] : Not available. Segmenticity Not available. : Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. : Conclusion/Summary [Product] : Not available. Carcinogenicity Nt available. : Conclusion/Summary [Product] : Not available. <td></td> <td></td> <td></td>			
Duration of treatment/exposure: 48 hours Amount/concentration applied: 5 % Conclusion/Summary [Product] : Not available. Serious eve damage/eve irritation Product/ingredient name Result Rabbit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available.			Amount/concentration applied. 500 ug i
Duration of treatment/exposure: 48 hours Amount/concentration applied: 5 % Conclusion/Summary [Product] : Not available. Serious eve damage/eve irritation Product/ingredient name Result Rabbit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available.	1.2-benzisothiazol-3(2H)-one		Human - Skin - Mild irritant
Amount/concentration applied: 5 % Conclusion/Summary (Product) : Not available. Serious eya damaga/eya irritation Product/ingredient name Result Rabbit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hourss Amount/concentration applied: 20 mg Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/Irritation Not available. Scin Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Bespiratory Conclusion/Summary [Product] : Not available. Sem coll mutagenicity Not available. Conclusion/Summary [Product] : Not available. Serm coll mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity That been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Conclusion	.,		
Conclusion/Summary [Product] : Not available. Berious ave damage/eye irritation Product/ingredient name Result Rabbit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/Irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Scin Conclusion/Summary [Product] : Not available. Conclusion/Summary [P			
Berious eye damage/eye irritation Product/ingredient name 2 (2-butoxyethoxy)ethanol Rabit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Rabit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Skin Conclusion/Summary [Product] : Not available. Serin cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Sarcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Pro			<u>ranound concontration applied</u> . 6 /6
Berious eye damage/eye irritation Product/ingredient name 2 (2-butoxyethoxy)ethanol Rabit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Rabit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Skin Conclusion/Summary [Product] : Not available. Serin cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Sarcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Pro	Conclusion (Summary [Dreduct]		
Product/ingredient name Result %(2-butoxyethoxy)ethanol Rabbit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory corrosion/summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Skin Conclusion/Summary [Product] : Not available. Sconclusion/Summary [Product] : Not available. Sem cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Sconclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available.	Conclusion/Summary [Product]	: Not available	
Product/ingredient name Result %(2-butoxyethoxy)ethanol Rabbit - Eyes - Moderate irritant Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory corrosion/summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Skin Conclusion/Summary [Product] : Not available. Sconclusion/Summary [Product] : Not available. Sem cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Sconclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available.			
F(2-butoxyethoxy)ethanol Rabbit - Eyes - Moderate irritant Duration of treatment/exposure 24 hours Amount/concentration applied: 20 mg Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/Irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Skin Conclusion/Summary [Product] : Not available. Segme cell mutagenicity Not available. Conclusion/Summary [Product] : Not availabl			
Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available.	Product/ingredient name		Result
Duration of treatment/exposure: 24 hours Amount/concentration applied: 20 mg Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available.	2-(2-butoxyethoxy)ethanol		Rabbit - Eves - Moderate irritant
Amount/concentration applied: 20 mg Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Severe eli mutagenicity Not available. Conclusion/Summary [Product] : Not available			
Rabbit - Eyes - Severe irritant Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. <td></td> <td></td> <td></td>			
Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] :			<u>ranoundooncontration applied</u> . 20 mg
Amount/concentration applied: 20 mg Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] :			Rabbit - Eves - Severe irritant
Conclusion/Summary [Product] : Not available. Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Bern cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Not available.			
Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantified leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Resproductive toxicity Not available.			<u> </u>
Respiratory corrosion/irritation Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantified leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Conclusion/Summary [Product] : Not available. Resproductive toxicity Not available.	Conclusion/Summary [Product]	• Not available	
Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available.		· Not available	•
Not available. Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available.	Despiratory compaier (invitation		
Conclusion/Summary [Product] : Not available. Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Respiratory It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available.			
Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Sarcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.	Not available.		
Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Sarcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.			
Respiratory or skin sensitization Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Sarcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.	Conclusion/Summary [Product]	: Not available	
Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Respiration of the symptotic of the symptotic arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Respiration of the symptote of the symp		· Not available	•
Not available. Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Respiration of the symptotic of the symptotic arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Respiration of the symptote of the symp	Peopiratory or okin considiration		
Skin Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Serm cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantif leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.			
Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantif leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.	Not available.		
Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantif leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.			
Conclusion/Summary [Product] : Not available. Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantif leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.	Skin		
Respiratory Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.		 Not available 	
Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantif leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.	oblicitation/outliniary [i roduct]		•
Conclusion/Summary [Product] : Not available. Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantif leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.	President and		
Germ cell mutagenicity Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.			
Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.	Conclusion/Summary [Product]	: Not available	
Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.			
Not available. Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantil leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.	Germ cell mutagenicity		
Conclusion/Summary [Product] : Not available. Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.			
Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.			
Carcinogenicity It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantit leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.		_	
It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantif leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Mot available. Reproductive toxicity Not available.	Conclusion/Summary [Product]	: Not available	
It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantif leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Mot available. Reproductive toxicity Not available.			
It has been observed that the carcinogenic hazard of this product arises when respirable dust is inhaled in quantif leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Mot available. Reproductive toxicity Not available.	Carcinogenicity		
leading to significant impairment of particle clearance mechanisms in the lung. Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.		anic hazard of	this product arises when respirable dust is inhaled in quantiti
Not available. Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.			
Conclusion/Summary [Product] : Not available. Reproductive toxicity Not available.			meenanisms in the lang.
Reproductive toxicity Not available.	Not avallable.		
Reproductive toxicity Not available.			
Not available.	Conclusion/Summary [Product]	: Not available	
Not available.			
Not available.	Reproductive toxicity		
Conclusion/Summary [Product] : Not available.			
Conclusion/Summary [Product] : Mot available.			
	Conclusion/Summary [Product]	: Not available	

SECTION 11: Toxicological information

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard	
Not available.	
Information on likely routes	of exposure
Not available.	
Potential acute health effect	<u>s</u>
Eye contact	: No known significant effects or critical hazards.
Inhalation	: No known significant effects or critical hazards.
Skin contact	: No known significant effects or critical hazards.
Ingestion	: No known significant effects or critical hazards.
Symptoms related to the ph	ysical, chemical and toxicological characteristics
Eye contact	: No specific data.
Inhalation	: No specific data.
Skin contact	: No specific data.
Ingestion	: No specific data.
Delayed and immediate effe	cts as well as chronic effects from short and long-term exposure
Short term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Long term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Potential chronic health effe	ects
Not available.	
Conclusion/Summary [Pro	duct] : Not available.
General	: No known significant effects or critical hazards.
Carcinogenicity	: No known significant effects or critical hazards.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.
11.2 Information on other has	arda

11.2 Information on other hazards

11.2.1 Endocrine disrupting properties

Not available.

Conclusion/Summary [Product]

: The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

11.2.2 Other information

Not available.

SECTION 12: Ecological information

12.1 Toxicity	
Product/ingredient name 2-(2-butoxyethoxy)ethanol	<mark>Result</mark> Acute - LC50 - Fresh water Fish - Bluegill - <i>Lepomis macrochirus</i> <u>Size</u> : 33 to 75 mm 1300000 μg/l [96 hours] <u>Effect</u> : Mortality
titanium dioxide	Acute - LC50 - Marine water Fish - Mummichog - <i>Fundulus heteroclitus</i> >1000000 μg/l [96 hours] <u>Effect</u> : Mortality
	Acute - LC50 - Fresh water Crustaceans - Water flea - <i>Ceriodaphnia dubia</i> - Neonate <u>Age</u> : <24 hours 3 mg/l [48 hours] <u>Effect</u> : Mortality
1,2-benzisothiazol-3(2H)-one	Acute - LC50 - Fresh water OECD [Fish, Acute Toxicity Test] Fish - Trout - <i>Onorhynchus Mykiss</i> 1.9 mg/l [96 hours]
	Acute - EC50 OECD 202 [Daphnia sp. Acute Immobilization Test and Reproduction Test] Daphnia - Daphnia - <i>Daphnia Magna</i> 3.7 mg/l [48 hours]
	Acute - EC50 - Marine water OECD 201 [Alga, Growth Inhibition Test] Algae - Algae - <i>Skeletonema Costatum</i> 0.36 mg/l [72 hours]
	Acute - NOEC - Marine water OECD 201 [Alga, Growth Inhibition Test] Algae - Algae - <i>Skeletonema Costatum</i> 0.15 mg/l [72 hours]
2-methyl-2H-isothiazol-3-one	Acute - EC50 - Fresh water US EPA Daphnia - Water flea - <i>Daphnia magna</i> <u>Age</u> : <24 hours 0.18 ppm [48 hours] <u>Effect</u> : Intoxication
	Acute - LC50 - Fresh water US EPA Fish - Rainbow trout,donaldson trout - <i>Oncorhynchus mykiss</i> <u>Weight</u> : 0.73 g 0.07 ppm [96 hours] <u>Effect</u> : Mortality
Conclusion/Summary [Product]	: Not available.
12.2 Persistence and degradability Product/ingredient name 7 ,2-benzisothiazol-3(2H)-one	<mark>Result</mark> EU 24% [28 days]
Conclusion/Summary [Product]	: Not available.

Date of issue/Date of revision AQUATOP VIRTA 22 - RAL 7015

: 30/05/2025 Date of previous issue

:06/11/2023

Product/ingredient name	Aquatic	Aquatic half-life		Photolysis		Biodegradability	
,2-benzisothiazol-3(2H)-one	-		-			Inherent	
.3 Bioaccumulative potenti	al		<u>+</u>			<u>.</u>	
Product/ingredient name	LogPow		E	BCF		Potential	
2-(2-butoxyethoxy)ethanol 1,2-benzisothiazol-3(2H)-one	1 -		- 3	.2		Low Low	
2.4 Mobility in soil							
Soil/water partition coefficie	ent						
Product/ingredient name		logKoc			Кос		
 2-(2-butoxyethoxy)ethanol adipohydrazide 1,2-benzisothiazol-3(2H)-one 2-methyl-2H-isothiazol-3-one 		1.56 1.74 1.86 1.74	1.74 1.86		36.5981 55.2165 73.142 54.9187		
Results of PMT and vPvM as	ssessme				01.0107		
Product/ingredient name	РМТ	Р	М	т	vPvM	vP	٧M
2-(2-butoxyethoxy)ethanol	No	No	No	No	No	No	No
titanium dioxide	No	No	No	No	No	No	No
adipohydrazide	No	No	No	No	No	No	No
1,2-benzisothiazol-3(2H)-one		No	No	No	No	No	No
2-methyl-2H-isothiazol-3-one	No	No	No	No	No	No	No
lobility	: Not av	/ailable.					
Conclusion/Summary	:	The produc	t does not	meet the crite	eria to be cons	idered as a	PMT or vPv
2.5 Results of PBT and vPvE	3 assessi	ment					
Regulation (EC) No. 1907/20	06 [REAG	CH]					
Product/ingredient name	PBT	Р	В	т	vPvB	vP	vB
2-(2-butoxyethoxy)ethanol	No	No	No	No	No	No	No
					INT.	NI-	N .
	No	No	No	No	No	No	No
titanium dioxide adipohydrazide	No	No No	No No	No No	No	NO NO	NO NO
titanium dioxide adipohydrazide 1,2-benzisothiazol-3(2H)-one 2-methyl-2H-isothiazol-3-one	No No						

Regulation (EC) No. 1272/2008 [CLP]

Product/ingredient name	PBT	Р	В	т	vPvB	vP	vB
2-(2-butoxyethoxy)ethanol	No	No	No	No	No	No	No
titanium dioxide	No	No	No	No	No	No	No
adipohydrazide	No	No	No	No	No	No	No
1,2-benzisothiazol-3(2H)-one	No	No	No	No	No	No	No
2-methyl-2H-isothiazol-3-one	No	No	No	No	No	No	No

Conclusion/Summary Regulation (EC) No. 1272/2008 [CLP] : The product does not meet the criteria to be considered as a PBT or vPvB.

12.6 Endocrine disrupting properties

Not available.

Conclusion/Summary [Product]

: The product does not meet the criteria to be considered as having endocrine disrupting properties according to the criteria set out in either Regulation (EC) No. 1907/2006 or Regulation (EC) No 1272/2008.

12.7 Other adverse effects

No known significant effects or critical hazards.

: 30/05/2025 Date of previous issue

SECTION 13: Disposal considerations

13.1 Waste treatment meth	ods
Product	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
European waste catalogue (EWC)	: 080112
Packaging	
Methods of disposal	: The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.
Special precautions	: This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.

SECTION 14: Transport information

	ADR/RID	ADN	IMDG	ΙΑΤΑ
14.1 UN number or ID number	Not regulated.	Not regulated.	Not regulated.	Not regulated.
14.2 UN proper shipping name	-	-	-	-
14.3 Transport hazard class(es)	-	-	-	-
14.4 Packing group	-	-	-	-
14.5 Environmental hazards	No.	No.	No.	No.

user

- **14.6 Special precautions for** : **Transport within user's premises:** always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.
- 14.7 Maritime transport in bulk according to IMO instruments
- : Not relevant/applicable due to nature of the product.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture EU Regulation (EC) No. 1907/2006 (REACH)

Annex XIV - List of substances subject to authorisation

Annex XIV

None of the components are listed.

Substances of very high concern

None of the components are listed.

Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

Date of issue/Date of revision : 30/05/2025 Date of previous issue AQUATOP VIRTA 22 - RAL 7015

:06/11/2023

Product/ingredient name	%	Designation [Usage]
2-(2-butoxyethoxy)ethanol	≤3	55 [Consumer paint]
Labelling :		
ther EU regulations		
Industrial emissions : Not lis (integrated pollution prevention and control) - Air	sted	
Industrial emissions : Not lis (integrated pollution prevention and control) - Water	sted	
Explosive precursors : Not a Ozone depleting substances (EU 20 Not listed.	oplicable. 124/590)	
Prior Informed Consent (PIC) (649/2 Not listed.	<u>:012/EU)</u>	
Persistent Organic Pollutants Not listed.		
Seveso Directive This product is not controlled under th	e Seveso Direct	ive.
nternational regulations		
hemical Weapon Convention List S Not listed.	chedules I, II &	<u>III Chemicals</u>
<u>Iontreal Protocol</u> Not listed.		
tockholm Convention on Persisten	t Organic Pollu	tants
Not listed.		
otterdam Convention on Prior Infor	med Consent (PIC)
Not listed.		
NECE Aarhus Protocol on POPs an	d Heavy Metals	<u>5</u>
Not listed.		
.2 Chemical safety : This p	product contains	substances for which Chemical Safety Assessments are sti

 \checkmark Indicates information that has changed from previously issued version.

Abbreviations and acronyms	 ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number SCG = Segregation Group
	RRN = REACH Registration Number SGG = Segregation Group vPvB = Very Persistent and Very Bioaccumulative

Date of issue/Date of revision	: 30/05/2025	Date of previous issue	:06/11/2023	Version : 2	14/16
AQUATOP VIRTA 22 - RAL 7015				Label No : 114	118

SECTION 16: Other information

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Not classified.

Full text of abbreviated H statements

H 301	Toxic if swallowed.
H302	Harmful if swallowed.
H311	Toxic in contact with skin.
H314	Causes severe skin burns and eye damage.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H330	Fatal if inhaled.
H351	Suspected of causing cancer.
H400	Very toxic to aquatic life.
H410	Very toxic to aquatic life with long lasting effects.
H411	Toxic to aquatic life with long lasting effects.
EUH071	Corrosive to the respiratory tract.

Full text of classifications [CLP/GHS]

Acute Tox. 2	ACUTE TOXICITY - Category 2
Acute Tox. 3	ACUTE TOXICITY - Category 3
Acute Tox. 4	ACUTE TOXICITY - Category 4
Aquatic Acute 1	SHORT-TERM (ACUTE) AQUATIC HAZARD - Category 1
Aquatic Chronic 1	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 1
Aquatic Chronic 2	LONG-TERM (CHRONIC) AQUATIC HAZARD - Category 2
Carc. 2	CARCINOGENICITY - Category 2
Eye Dam. 1	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 1
Eye Irrit. 2	SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2
Skin Corr. 1B	SKIN CORROSION/IRRITATION - Category 1B
Skin Irrit. 2	SKIN CORROSION/IRRITATION - Category 2
Skin Sens. 1	SKIN SENSITISATION - Category 1
Skin Sens. 1A	SKIN SENSITISATION - Category 1A
Date of issue/ Date of	: 30/05/2025
revision	
Date of previous issue	e : 06/11/2023
Version	: 2

Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision AQUATOP VIRTA 22 - RAL 7015

: 30/05/2025 Date of previous issue

:06/11/2023

 Version
 : 2
 16/16

 Label No
 : 11/14118